Examples of 'olaratumab' in a sentence
Meaning of "olaratumab"
Olaratumab is a noun that represents a monoclonal antibody drug used in the treatment of certain types of cancer. It works by helping the immune system slow or stop the growth of cancer cells
Show more definitions
- A particular monoclonal antibody.
How to use "olaratumab" in a sentence
Basic
Advanced
olaratumab
Olaratumab and doxorubicin were administered by intravenous infusion.
It is not known whether olaratumab is excreted in human milk.
Olaratumab is administered as an intravenous infusion only.
There are no data on the effect of olaratumab on human fertility.
Olaratumab is a human monoclonal antibody.
The active substance is olaratumab.
Olaratumab for the treatment of advanced soft tissue sarcoma.
Posology adjustments for olaratumab.
Olaratumab therapy must be initiated and supervised by physicians experienced in oncology.
All anaphylactic reactions occurred during the first olaratumab infusion.
The calculated volume of olaratumab should be aseptically transferred to the intravenous container.
The majority of these reactions occurred during or following the first olaratumab infusion.
There have been no formal studies with olaratumab in patients with hepatic impairment.
Olaratumab is an antineoplastic.
There have been no formal studies with olaratumab in patients with renal impairment.
See also
Adding olaratumab to standard chemotherapy did not significantly increase treatment side effects.
Aseptically transfer the calculated volume of olaratumab into an empty intravenous infusion container.
All severe IRRs occurred during or immediately after the first administration of olaratumab.
The calculated volume of olaratumab should be aseptically transferred into an empty intravenous infusion container.
Vaccination with a live vaccine should be avoided in patients receiving olaratumab in combination with doxorubicin.
The dose and volume of olaratumab needed should be calculated to prepare the infusion solution.
Each millilitre of the concentrate for solution for infusion contains 10 mg of olaratumab.
There are very limited data regarding olaratumab administration in patients with moderate hepatic impairment.
Olaratumab is associated with serious risks, including infusion-related reactions and embryofetal harm.
Recommendations for the management of olaratumab IRRs are provided in table 1.
Conversely, olaratumab is not anticipated to affect the pharmacokinetics of co-administered medicinal products.
In case of recurrence of a Grade 4 toxicity, treatment with olaratumab should be permanently discontinued.
As a result, in vitro olaratumab inhibits PDGFR-α pathway signalling in tumour and stromal cells.
In a dedicated DDI study, no pharmacokinetic interactions were observed in patients between olaratumab and doxorubicin.
For the first eight cycles, olaratumab is administered with doxorubicin.
When olaratumab attaches to PDGFR-α it may prevent cancer cell growth and survival.
What Lartruvo contains - The active substance is olaratumab.
By blocking this protein, olaratumab can make some tumors shrink or stop growing.
Lartruvo 10 mg / mL concentrate for solution for infusion olaratumab.
Patients receiving olaratumab and doxorubicin are at risk of neutropenia see section 4.8.
One mL of concentrate contains 10 mg of olaratumab.
Olaratumab is given by intravenous ( into a vein ) infusion, over one hour.
One mL of concentrate for solution for infusion contains 10 mg of olaratumab.
Patients receiving olaratumab and doxorubicin are at risk of haemorrhagic events see section 4.8.
Infusion-related reactions ( IRRs ), including anaphylactic reactions, were reported in clinical trials with olaratumab.
Olaratumab recognises and attaches specifically to a protein known as platelet-derived growth factor receptor-α PDGFR-α.
Handling instructions Lartruvo 10 mg / mL concentrate for solution for infusion olaratumab.
Olaratumab is a human IgG1 monoclonal antibody produced in murine ( NS0 ) cells by recombinant DNA technology.
Infusion-related reactions ( IRRs ) Recommendations for the management of olaratumab IRRs are provided in table 1.
Olaratumab is a platelet-derived growth factor ( PDGF ) receptor-alpha blocking antibody.
Olaratumab ( Lartruvo ) is a platelet-derived growth factor receptor - alpha-blocking antibody.
Olaratumab was originally developed by ImClone Systems, which was acquired by Eli Lilly in 2008.
